It’s Thanksgiving week! We’ll plan on publishing the Daily on Monday/Tuesday, then take the rest of the week off from news reporting. Unless somebody buys somebody else. That, we’ll report!
Sanofi chief wants to do things differently. Liked this juicy quote: Mr Viehbacher added: “The best scientists are often lousy leaders [and] managers. You had a research and development god who hoped a blockbuster emerged. When it didn’t, you merged. The model was flawed. I think the mistake we made in our industry was, we made R&D organisations that were very big, very complex, very difficult to manage, and we killed the innovative spirit”…more
Morphine – kill pain, grow tumors?? – Two new studies add to growing evidence that morphine and other opiate-based painkillers may promote the growth and spread of cancer cells…more
Pfizer reaps one of the consequences of merging: inherited lawsuits – Two Pfizer Inc. units’ hormone- replacement therapy drugs caused an Illinois woman’s breast cancer, making them liable for at least $6.3 million in damages, a Philadelphia jury ruled today…more
B-I hoping to take a big bite out of warfarin – Just 2.4 percent of patients given Pradaxa for six months after their initial treatment developed clots in the legs and lungs, similar to the 2.2 percent rate for those given the generic drug warfarin, according to an abstract of the so-called Recover study posted on the American Society of Hematology Web site last week. There was no increased risk of major bleeding, a complication of blood-thinning treatments…more
Specialty/Oncology training and development. If you’re looking to enhance your training program for specialty reps, we have just the providers for you. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
What about that pesky Social Media/ROI question? My thoughts…
JUST FOR FUN
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Connect with Steve Woodruff